Indian government forces Bayer to accept generic Nexavar competition – FiercePharma

India has invoked its compulsory licensing rules for the first time, allowing the domestic drugmaker Natco Pharma to make and sell a version of Bayer’s cancer drug Nexavar–despite the fact that Nexavar is still on patent. We think this is quite a significant development. What does it mean for ROI of big pharma companies R&D ? What does it mean for IP integrity for doing business in India ? Indian government forces Bayer to accept generic Nexavar competition – FiercePharma.

To read the full article, please login. The full content of this article and all premium articles is available exclusively for site members.
Site membership is free. If you are an existing user, please login. New users may register below.

Existing Users Log In

fourteen − 3 =

   
New User Registration
Please indicate that you agree to the Terms of Service

four × two =

*Required field

Christian Schumacher

Dr. Christian Schumacher is the founder and managing director of StepChange Innovations GmbH, a technology development and consulting firm based in Germany. He has 30 years of experience in the chemical industry with global players such as Hoechst, DyStar and Archroma in various senior managemnet roles.